C12Y 301/06
Sulfuric ester hydrolases
Official title: Sulfuric ester hydrolases (3.1.6)
C12Y301/06 (Sulfuric ester hydrolases) appears on 152 US grants and 310 published applications in this corpus.
Search patents in C12Y- Granted patents
- 152
- Published applications
- 310
- Assignees
- 108
- Inventors
- 495
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 2 |
| 2004 | 0 | 3 |
| 2005 | 2 | 5 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 1 | 3 |
| 2009 | 0 | 6 |
| 2010 | 0 | 2 |
| 2011 | 3 | 5 |
| 2012 | 3 | 10 |
| 2013 | 5 | 12 |
| 2014 | 6 | 17 |
| 2015 | 13 | 17 |
| 2016 | 8 | 17 |
| 2017 | 9 | 11 |
| 2018 | 10 | 22 |
| 2019 | 10 | 23 |
| 2020 | 12 | 28 |
| 2021 | 12 | 23 |
| 2022 | 15 | 21 |
| 2023 | 7 | 20 |
| 2024 | 19 | 21 |
| 2025 | 10 | 29 |
| 2026 | 4 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 301/06013Iduronate-2-sulfatase77
- C12Y 301/06008Cerebroside-sulfatase32
- C12Y 301/06001Arylsulfatase18
- C12Y 301/06004N-acetylgalactosamine-6-sulfatase15
- C12Y 301/06014N-acetylglucosamine-6-sulfatase14
- C12Y 301/06012N-acetylgalactosamine-4-sulfatase3
- C12Y 301/06011Disulfoglucosamine-6-sulfatase1
- C12Y 301/06002Steryl-sulfatase0
All 17 subgroupsShow fewer
- C12Y 301/06003Glycosulfatase0
- C12Y 301/06006Choline-sulfatase0
- C12Y 301/06007Cellulose-polysulfatase0
- C12Y 301/06009Chondro-4-sulfatase0
- C12Y 301/0601Chondro-6-sulfatase0
- C12Y 301/06015N-sulfoglucosamine-3-sulfatase0
- C12Y 301/06016Monomethyl-sulfatase0
- C12Y 301/06017D-lactate-2-sulfatase0
- C12Y 301/06018Glucuronate-2-sulfatase0
Recent patents
- AAV-IDS vectors for treatment of mucopolysaccharidosis II7 Jul 2026US 12,673,117 B2The University of North Carolina at Chapel Hill
- Formulations of protein molecules comprising iduronate 2-sulfatase30 Jun 2026US 12,667,606 B2Denali Therapeutics Inc.
- Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic26 May 2026US 12,636,353 B2The Regents of the University of California
- Anti-transferrin receptor fusion proteins and methods of use thereof26 May 2026US 12,636,363 B2Denali Therapeutics Inc.
- CNS delivery of therapeutic agents9 Sep 2025US 12,409,210 B2Takeda Pharmaceutical Company Limited
- Novel glycan compounds for age-related macular degeneration8 Oct 2026US 2026/0306530 A1The Regents of the University of California
- Gene therapy for treating mucopolysaccharidosis type ii1 Oct 2026US 2026/0295085 A1The Trustees of the University of Pennsylvania
- Peptide Having Affinity for Human Transferrin Receptor24 Sep 2026US 2026/0285942 A1JCR Pharmaceuticals Co., Ltd.
- Method for improving neurological function in mpsi and mpsii and other neurological disorders20 Aug 2026US 2026/0241038 A1Regents of the University of Minnesota
- Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier2 Jul 2026US 2026/0184781 A1JCR Pharmaceuticals Co., Ltd.
Most cited
By later US patents
- Delivery of therapeutic compounds to the brain and other tissues90US 7,442,372 B2Biomarin Pharmaceutical Inc. · 2008
- Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases78US 9,249,424 B2HealthPartners Research & Education · 2016
- Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor61US 5,695,752 AThe Regents of the University of California · 1997
- Sulfate ligands for L-selectins and methods of preventing sulfate addition53US 5,580,862 AThe Regents of the University of California · 1996
- Cleavable lipids30US 9,717,690 B2RaNA Therapeutics, Inc. · 2017